Vertex Pharmaceuticals Stock Edges Up 0.07% Despite Market Volatility
May 10, 2023
Trending News 🌥️
Vertex ($NASDAQ:VERX) Pharmaceuticals Inc. (VERTEX) shares slightly rose by 0.07% to $346.59 on Thursday, despite the stock market having a difficult day. This is impressive considering the broad-market volatility that has been ongoing for the past few weeks. VERTEX is a biotechnology company that specializes in developing and commercializing innovative therapies for treating serious diseases. Their main focus is on diseases such as cystic fibrosis, sickle cell disease, and other autoimmune and rare diseases. VERTEX is currently in the process of expanding its product portfolio and launching new treatments for cystic fibrosis and other diseases.
In addition, the company has developed a pipeline of new compounds that are being tested for potential treatments for cardiovascular and infectious diseases. VERTEX’s stock has shown strong performance in recent months, with investors viewing the company favorably due to its promising pipeline of products and treatments.
Analysis
At GoodWhale, we have completed an extensive analysis of VERTEX’s wellbeing. Our Risk Rating determined it to be a medium risk investment in terms of both financial and business aspects. During our investigation, we detected one risk warning in the cashflow statement which was concerning. If you become a registered user, you can check out this warning and review our full assessment. Vertex_Pharmaceuticals_Stock_Edges_Up_0.07_Despite_Market_Volatility”>More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Vertex. More…
| Total Revenues | Net Income | Net Margin |
| 491.62 | -12.3 | -2.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Vertex. More…
| Operations | Investing | Financing |
| 76.85 | -85.05 | 17.09 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Vertex. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 719.19 | 489.47 | 1.53 |
Key Ratios Snapshot
Some of the financial key ratios for Vertex are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 15.2% | – | -1.6% |
| FCF Margin | ROE | ROA |
| 0.7% | -2.3% | -0.7% |
Peers
The company was founded in 1978 and is headquartered in Berwyn, Pennsylvania. Vertex Inc has several competitors, including KLDiscovery Inc, TKC Corp, and Business-intelligence of Oriental Nations Corp Ltd.
– KLDiscovery Inc ($OTCPK:KLDI)
KLDiscovery Inc is a global provider of electronic discovery, data recovery, and litigation support services. The company has a market cap of 106.98M as of 2022 and a Return on Equity of -7.61%. KLDiscovery Inc provides services to law firms, corporations, and government agencies worldwide. The company offers a full range of services, from data collection and processing to document review and trial preparation.
– TKC Corp ($TSE:9746)
TKC Corp is a publicly traded company with a market cap of 199.69B as of 2022. The company has a Return on Equity of 9.32%. TKC Corp is a diversified conglomerate with businesses in a variety of industries including construction, real estate, hospitality, and health care. The company has a strong presence in the United States, Asia, and Europe.
– Business-intelligence of Oriental Nations Corp Ltd ($SZSE:300166)
Oriental Nations Corp Ltd is a 9.89B market cap company with a ROE of 1.79%. The company is involved in the business of intelligence and information technology.
Summary
The stock is highly volatile, but could be attractive for investors with a higher risk tolerance.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
